Literature DB >> 1332930

Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.

D A Boothman1, M Wang, R A Schea, H L Burrows, S Strickfaden, J K Owens.   

Abstract

Little is known about the molecular mechanisms responsible for the survival recovery process(es) (known as potentially lethal damage repair), which occurs in mammalian cells following ionizing radiation. Previously, we presented data indicating a role for the DNA unwinding enzyme, topoisomerase I, in DNA repair. We now demonstrate that camptothecin, a specific inhibitor of topoisomerase I, causes dramatic radiosensitization of an extremely resistant human melanoma (U1-Mel) cell line. Camptothecin radiosensitized U1-Mel cells when it was administered either during or immediately following x-irradiation. U1-Mel cells were optimally radiosensitized with 4 microM camptothecin for a period of 4-6 hrs after x-irradiation. Enhanced cell killing by camptothecin was proportional to the initial extent of damage created by x-irradiation; the higher the dose of ionizing radiation, the greater the radiosensitization. The apparent synergy observed with camptothecin and x-rays was irreversible; camptothecin-treated U1-Mel cells were not able to carry out PLDR in a 48 hr period after the drug was removed. We hypothesize that the administration of camptothecin causes lesion modification through a topoisomerase I-mediated mechanism. These data support a role for topoisomerase I in DNA repair and indicate that camptothecin, or more effective derivatives, may have clinical use.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1332930     DOI: 10.1016/0360-3016(92)90478-z

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

3.  Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.

Authors:  Dana L Casey; Yueh-Yun Chi; Sarah S Donaldson; Douglas S Hawkins; Jing Tian; Carola A Arndt; David A Rodeberg; Jonathan C Routh; Timothy B Lautz; Abha A Gupta; Torunn I Yock; Suzanne L Wolden
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

4.  Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide.

Authors:  I Gradzka; T Iwaneńko; M Kruszewski; I Szumiel; M Kapiszewska; C S Lange; G Afanasjev
Journal:  Radiat Environ Biophys       Date:  1996-08       Impact factor: 1.925

5.  The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.

Authors:  J P Lamond; M P Mehta; D A Boothman
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

Review 6.  Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

Authors:  M T Jennings; S Iyengar
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

7.  Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.

Authors:  K Tamura; M Takada; I Kawase; T Tada; S Kudoh; K Okishio; M Fukuoka; N Yamaoka; Y Fujiwara; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1997-02

8.  Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.

Authors:  S M Planchon; S Wuerzberger; B Frydman; D T Witiak; P Hutson; D R Church; G Wilding; D A Boothman
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 13.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.